Manuel Gellar
Influenza B virus poses a significant public health threat, particularly during seasonal outbreaks. Traditional treatments and vaccines have limited efficacy against diverse and evolving strains. In this context, antibodies targeting conserved viral components offer a promising therapeutic avenue. This article delves into the effector-independent in vivo activity of a robust influenza B neuraminidase (NA) widely neutralizing antibody (WNA). We explore the antibody’s mechanism, efficacy, and potential implications for future influenza therapies. Our literature review examines previous research on NA-targeting antibodies, while the discussion considers the antibody's therapeutic potential, advantages, and limitations. The conclusion highlights the significance of these findings in the broader context of influenza management.
ఈ కథనాన్ని భాగస్వామ్యం చేయండి
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 